Fact CheckerSign in

NCT05747443Active, not recruiting

Multilevel Interventions to Increase Adherence to Lung Cancer Screening

Source: ClinicalTrials.gov · Last updated 24 Dec 2025

Brief summary (registry, in English)

Screening for lung cancer has the potential for a profound public health benefit. Repeat annual screening is necessary for early detection of lung cancer. The investigators will test two interventions which include patient education and reminders to improve adherence to lung cancer screening.

Status (registry)
Active, not recruiting
Study type
Interventional
Enrollment
1837 (actual)
First submitted
17 Feb 2023
Start date
12 Dec 2022
Primary completion date
5 Jul 2025
Lead sponsor
Kaiser Permanente
Diseases
Lung cancer
NCT number
NCT05747443

What you commit to

  • Study type: Interventional
  • Participants enrolled: 1837
  • From 12 Dec 2022 to the primary completion date, 5 Jul 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Patients who were previously diagnosed with lung cancer,

Other

  • Patients who have a positive scan,
  • Patients who have an indicator for interpreter services, except for Spanish

Who the study is looking for

  • KPWA members
  • Aged 50-78 years
  • Have a negative screening LDCT scan
  • Speak English or Spanish
  • Meet US Preventive Services Task Force guidelines

Age in the registry: 50 years to 78 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Kaiser Permanente
Coordinator of this site? Confirm its status
SeattleUnited StatesUnknown status

Related publications

This page is information, not medical advice. Discuss any trial with your doctor.